{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T00:59:04Z","timestamp":1795136344931,"version":"4.10.3"},"reference-count":52,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,11,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The nuclear export protein XPO1 is overexpressed in cancer, leading to the cytoplasmic mislocalization of multiple tumor suppressor proteins. Existing XPO1-targeting agents lack selectivity and have been associated with significant toxicity. Small molecule selective inhibitors of nuclear export (SINEs) were designed that specifically inhibit XPO1. Genetic experiments and X-ray structures demonstrate that SINE covalently bind to a cysteine residue in the cargo-binding groove of XPO1, thereby inhibiting nuclear export of cargo proteins. The clinical relevance of SINEs was explored in chronic lymphocytic leukemia (CLL), a disease associated with recurrent XPO1 mutations. Evidence is presented that SINEs can restore normal regulation to the majority of the dysregulated pathways in CLL both in vitro and in vivo and induce apoptosis of CLL cells with a favorable therapeutic index, with enhanced killing of genomically high-risk CLL cells that are typically unresponsive to traditional therapies. More importantly, SINE slows disease progression, and improves overall survival in the E\u03bc-TCL1-SCID mouse model of CLL with minimal weight loss or other toxicities. Together, these findings demonstrate that XPO1 is a valid target in CLL with minimal effects on normal cells and provide a basis for the development of SINEs in CLL and related hematologic malignancies.<\/jats:p>","DOI":"10.1182\/blood-2012-05-429506","type":"journal-article","created":{"date-parts":[[2012,10,4]],"date-time":"2012-10-04T21:13:25Z","timestamp":1349385205000},"page":"4621-4634","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":271,"title":["Selective inhibitors of nuclear export show that CRM1\/XPO1 is a target in chronic lymphocytic leukemia"],"prefix":"10.1182","volume":"120","author":[{"given":"Rosa","family":"Lapalombella","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingxiang","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, University of Texas Southwestern Medical Center Dallas, Dallas, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Williams","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Tangeman","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Jha","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Zhong","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Goettl","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Mahoney","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Berglund","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sneha","family":"Gupta","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Farmer","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, University of Texas Southwestern Medical Center Dallas, Dallas, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeswaran","family":"Mani","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy J.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH;"},{"name":"Divisions of Medicinal Chemistry and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lucas","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH;"},{"name":"Medicinal Chemistry and Pharmacognosy, College of Pharmacy, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaokui","family":"Mo","sequence":"additional","affiliation":[{"name":"Center for Biostatistics, The Ohio State University, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Daelemans","sequence":"additional","affiliation":[{"name":"Rega Institute for Medical Research, KU Leuven, Leuven, Belgium; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Sandanayaka","sequence":"additional","affiliation":[{"name":"Karyopharm Therapeutics Inc, Natick, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Shechter","sequence":"additional","affiliation":[{"name":"Karyopharm Therapeutics Inc, Natick, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilara","family":"McCauley","sequence":"additional","affiliation":[{"name":"Karyopharm Therapeutics Inc, Natick, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Shacham","sequence":"additional","affiliation":[{"name":"Karyopharm Therapeutics Inc, Natick, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kauffman","sequence":"additional","affiliation":[{"name":"Karyopharm Therapeutics Inc, Natick, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuh Min","family":"Chook","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, University of Texas Southwestern Medical Center Dallas, Dallas, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH;"},{"name":"Divisions of Medicinal Chemistry and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"6","key":"2019111809053937300_B1","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.sbi.2010.09.008","article-title":"Recognition of nuclear targeting signals by Karyopherin-beta proteins.","volume":"20","author":"Xu","year":"2010","journal-title":"Curr Opin Struct Biol"},{"issue":"17","key":"2019111809053937300_B2","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1038\/emboj.2011.287","article-title":"Ran-dependent nuclear export mediators: a structural perspective.","volume":"30","author":"G\u00fcttler","year":"2011","journal-title":"EMBO J"},{"key":"2019111809053937300_B3","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/nature07975","article-title":"Structural basis for leucine-rich nuclear export signal recognition by CRM1.","volume":"458","author":"Dong","year":"2009","journal-title":"Nature"},{"issue":"1","key":"2019111809053937300_B4","first-page":"229","article-title":"The expression of CRM1 is associated with prognosis in human osteosarcoma.","volume":"21","author":"Yao","year":"2009","journal-title":"Oncol Rep"},{"issue":"5930","key":"2019111809053937300_B5","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1126\/science.1173388","article-title":"Crystal structure of the nuclear export receptor CRM1 in complex with Snurportin1 and RanGTP.","volume":"324","author":"Monecke","year":"2009","journal-title":"Science"},{"issue":"11","key":"2019111809053937300_B6","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/nsmb.1931","article-title":"NES consensus redefined by structures of PKI-type and Rev-type nuclear export signals bound to CRM1.","volume":"17","author":"G\u00fcttler","year":"2010","journal-title":"Nat Struct Mol Biol"},{"issue":"12","key":"2019111809053937300_B7","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1038\/emboj.2010.89","article-title":"An allosteric mechanism to displace nuclear export cargo from CRM1 and RanGTP by RanBP1.","volume":"29","author":"Koyama","year":"2010","journal-title":"EMBO J"},{"issue":"6","key":"2019111809053937300_B8","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.ceb.2008.09.010","article-title":"Reorganization of the nuclear envelope during open mitosis.","volume":"20","author":"Kutay","year":"2008","journal-title":"Curr Opin Cell Biol"},{"issue":"26","key":"2019111809053937300_B9","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.2174\/092986708786242859","article-title":"CRM1-mediated nuclear export of proteins and drug resistance in cancer.","volume":"15","author":"Turner","year":"2008","journal-title":"Curr Med Chem"},{"issue":"8","key":"2019111809053937300_B10","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.bcp.2011.12.016","article-title":"Nuclear export of proteins and drug resistance in cancer.","volume":"83","author":"Turner","year":"2012","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"2019111809053937300_B11","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1227\/01.NEU.0000348550.47441.4B","article-title":"Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis.","volume":"65","author":"Shen","year":"2009","journal-title":"Neurosurgery"},{"issue":"3","key":"2019111809053937300_B12","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMoa041974","article-title":"Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.","volume":"352","author":"Falini","year":"2005","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111809053937300_B13","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.blre.2011.06.001","article-title":"Acute myeloid leukemia with mutated nucleophosmin (NPM1): any hope for a targeted therapy?","volume":"25","author":"Falini","year":"2011","journal-title":"Blood Rev"},{"issue":"20","key":"2019111809053937300_B14","doi-asserted-by":"crossref","first-page":"8874","DOI":"10.1128\/MCB.25.20.8874-8886.2005","article-title":"Nucleophosmin is required for DNA integrity and p19Arf protein stability.","volume":"25","author":"Colombo","year":"2005","journal-title":"Mol Cell Biol"},{"issue":"2","key":"2019111809053937300_B15","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrc1274","article-title":"Nuclear transport and cancer: from mechanism to intervention.","volume":"4","author":"Kau","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"2019111809053937300_B16","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1006\/excr.1999.4433","article-title":"An inhibitor of nuclear export activates the p53 response and induces the localization of HDM2 and p53 to U1A-positive nuclear bodies associated with the PODs.","volume":"248","author":"La\u00edn","year":"1999","journal-title":"Exp Cell Res"},{"issue":"2","key":"2019111809053937300_B17","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1006\/excr.1999.4672","article-title":"Accumulating active p53 in the nucleus by inhibition of nuclear export: a novel strategy to promote the p53 tumor suppressor function.","volume":"253","author":"La\u00edn","year":"1999","journal-title":"Exp Cell Res"},{"issue":"2","key":"2019111809053937300_B18","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1158\/0008-5472.CAN-08-0858","article-title":"Identification of nuclear export inhibitors with potent anticancer activity in vivo.","volume":"69","author":"Mutka","year":"2009","journal-title":"Cancer Res"},{"issue":"2","key":"2019111809053937300_B19","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/BF00256156","article-title":"In vivo and in vitro anticancer activity of the structurally novel and highly potent antibiotic CI-940 and its hydroxy analog (PD 114,721).","volume":"16","author":"Roberts","year":"1986","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"2019111809053937300_B20","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/bjc.1996.415","article-title":"Phase I trial of elactocin.","volume":"74","author":"Newlands","year":"1996","journal-title":"Br J Cancer"},{"issue":"6","key":"2019111809053937300_B21","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s00280-010-1434-6","article-title":"p53-Dependent anticancer effects of leptomycin B on lung adenocarcinoma.","volume":"67","author":"Shao","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"issue":"21","key":"2019111809053937300_B22","doi-asserted-by":"crossref","first-page":"9487","DOI":"10.1016\/j.bmc.2008.09.051","article-title":"Inhibition of the CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates: structure-activity relationship and mechanism of action.","volume":"16","author":"Van Neck","year":"2008","journal-title":"Bioorg Med Chem"},{"issue":"6733","key":"2019111809053937300_B23","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/20375","article-title":"Structure of the nuclear transport complex karyopherin-beta2-Ran x GppNHp.","volume":"399","author":"Chook","year":"1999","journal-title":"Nature"},{"issue":"13","key":"2019111809053937300_B24","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1182\/blood-2009-09-242438","article-title":"Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.","volume":"115","author":"Lapalombella","year":"2010","journal-title":"Blood"},{"issue":"13","key":"2019111809053937300_B25","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1182\/blood-2008-01-133108","article-title":"Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells.","volume":"112","author":"Lapalombella","year":"2008","journal-title":"Blood"},{"issue":"16","key":"2019111809053937300_B26","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1182\/blood-2010-11-315705","article-title":"The role of phosphatidylinositol 3-kinase-delta in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia.","volume":"117","author":"Herman","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2019111809053937300_B27","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1182\/blood-2005-12-011213","article-title":"Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia.","volume":"108","author":"Johnson","year":"2006","journal-title":"Blood"},{"issue":"2","key":"2019111809053937300_B28","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1083\/jcb.145.2.255","article-title":"CRM1-mediated recycling of snurportin 1 to the cytoplasm.","volume":"145","author":"Paraskeva","year":"1999","journal-title":"J Cell Biol"},{"issue":"2","key":"2019111809053937300_B29","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1074-5521(97)90257-X","article-title":"Leptomycin B is an inhibitor of nuclear export: inhibition of nucleo-cytoplasmic translocation of the human immunodeficiency virus type 1 (HIV-1) Rev protein and Rev-dependent mRNA.","volume":"4","author":"Wolff","year":"1997","journal-title":"Chem Biol"},{"issue":"2","key":"2019111809053937300_B30","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1128\/MCB.25.2.728-739.2005","article-title":"Kinetic and molecular analysis of nuclear export factor CRM1 association with its cargo in vivo.","volume":"25","author":"Daelemans","year":"2005","journal-title":"Mol Cell Biol"},{"issue":"8","key":"2019111809053937300_B31","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/ijc.24146","article-title":"The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation.","volume":"124","author":"van der Watt","year":"2009","journal-title":"Int J Cancer"},{"issue":"1","key":"2019111809053937300_B32","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrc2764","article-title":"From pathogenesis to treatment of chronic lymphocytic leukaemia.","volume":"10","author":"Zenz","year":"2010","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"2019111809053937300_B33","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2007-05-089037","article-title":"The Akt\/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells.","volume":"111","author":"Longo","year":"2008","journal-title":"Blood"},{"issue":"4","key":"2019111809053937300_B34","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.4049\/jimmunol.164.4.2200","article-title":"Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells.","volume":"164","author":"Furman","year":"2000","journal-title":"J Immunol"},{"key":"2019111809053937300_B35","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1182\/asheducation-2010.1.481","article-title":"Understanding and managing ultra high-risk chronic lymphocytic leukemia.","volume":"2010","author":"Stilgenbauer","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"2","key":"2019111809053937300_B36","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1182\/blood-2004-07-2761","article-title":"Apoptosis-based therapies for hematologic malignancies.","volume":"106","author":"Reed","year":"2005","journal-title":"Blood"},{"issue":"3","key":"2019111809053937300_B37","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1182\/blood-2004-03-0889","article-title":"Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha.","volume":"106","author":"Nishio","year":"2005","journal-title":"Blood"},{"issue":"20","key":"2019111809053937300_B38","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1182\/blood-2009-07-233718","article-title":"Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance.","volume":"114","author":"Kurtova","year":"2009","journal-title":"Blood"},{"issue":"4","key":"2019111809053937300_B39","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1182\/blood.V85.4.997.bloodjournal854997","article-title":"Functionally distinct human marrow stromal cell lines immortalized by transduction with the human papilloma virus E6\/E7 genes.","volume":"85","author":"Roecklein","year":"1995","journal-title":"Blood"},{"issue":"6","key":"2019111809053937300_B40","doi-asserted-by":"crossref","first-page":"e10941","DOI":"10.1371\/journal.pone.0010941","article-title":"The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo.","volume":"5","author":"Lucas","year":"2010","journal-title":"PLoS One"},{"issue":"18","key":"2019111809053937300_B41","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1091\/mbc.e12-01-0045","article-title":"NESdb: a database of NES-containing CRM1 cargos.","volume":"23","author":"Xu","year":"2012","journal-title":"Mol Biol Cell"},{"issue":"17","key":"2019111809053937300_B42","doi-asserted-by":"crossref","first-page":"6899","DOI":"10.1158\/0008-5472.CAN-09-0484","article-title":"Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition.","volume":"69","author":"Turner","year":"2009","journal-title":"Cancer Res"},{"issue":"10","key":"2019111809053937300_B43","doi-asserted-by":"crossref","first-page":"4395","DOI":"10.1128\/MCB.24.10.4395-4406.2004","article-title":"Nuclear export of phosphorylated galectin-3 regulates its antiapoptotic activity in response to chemotherapeutic drugs.","volume":"24","author":"Takenaka","year":"2004","journal-title":"Mol Cell Biol"},{"issue":"8","key":"2019111809053937300_B44","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1002\/cncr.23354","article-title":"Expression of the nuclear export protein chromosomal region maintenance\/exportin 1\/Xpo1 is a prognostic factor in human ovarian cancer.","volume":"112","author":"Noske","year":"2008","journal-title":"Cancer"},{"issue":"22","key":"2019111809053937300_B45","doi-asserted-by":"crossref","first-page":"14440","DOI":"10.1073\/pnas.212285299","article-title":"A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export.","volume":"99","author":"Daelemans","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"2019111809053937300_B46","doi-asserted-by":"crossref","first-page":"3922","DOI":"10.1182\/blood-2011-01-333138","article-title":"CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity.","volume":"118","author":"Sakakibara","year":"2011","journal-title":"Blood"},{"issue":"7","key":"2019111809053937300_B47","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1158\/1078-0432.CCR-06-2294","article-title":"Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity.","volume":"13","author":"Hussain","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2019111809053937300_B48","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1200\/JCO.2003.06.012","article-title":"Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance.","volume":"21","author":"Bannerji","year":"2003","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111809053937300_B49","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1182\/blood.V91.9.3379","article-title":"Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses.","volume":"91","author":"Kitada","year":"1998","journal-title":"Blood"},{"issue":"1","key":"2019111809053937300_B50","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/blood.V100.1.194","article-title":"Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells.","volume":"100","author":"Derenne","year":"2002","journal-title":"Blood"},{"issue":"28","key":"2019111809053937300_B51","doi-asserted-by":"crossref","first-page":"4818","DOI":"10.1038\/sj.onc.1207648","article-title":"Mcl-1 is required for Akata6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage.","volume":"23","author":"Michels","year":"2004","journal-title":"Oncogene"},{"issue":"21","key":"2019111809053937300_B52","first-page":"2622","article-title":"KPT-SINE, a potent, small molecule inhibitor of CRM1-dependent nuclear-cytoplasmic shuttling, with potent activity against T-ALL and AML [abstract].","volume":"118","author":"Etchin","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/23\/4621\/1361381\/zh804912004621.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/23\/4621\/1361381\/zh804912004621.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T10:09:37Z","timestamp":1574071777000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/120\/23\/4621\/30910\/Selective-inhibitors-of-nuclear-export-show-that"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,29]]},"references-count":52,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2012,11,29]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-05-429506","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717972961.793469752","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,29]]}}}